Posted on December 2, 2020 by Sitemaster
Yesterday the US Food and Drug Administration (FDA) gave its approval for the first gallium-68 prostate-specific membrane antigen imaging agent (Ga-67 PSMA-11), for the use in association with positron emission tomography (PET) scanning for the evaluation of men with suspected prostate cancer — and most particularly for those men with high-risk characteristics suggesting the possibility of metastasis, including men with newly diagnosed or recurrent disease. However, here’s the “but”… READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: gallium-68, imaging, PET, PSMA, scan | 5 Comments »
Posted on March 1, 2020 by Sitemaster
Members of the Coalition for Biomedical Imaging and Bioengineering Research (CIBR) are interested in patient perspectives and experiences in relation to imaging in the diagnosis, work-up, and management of men with or suspected of having prostate cancer. … READ MORE …
Filed under: Uncategorized | Tagged: imaging, survey | 1 Comment »
Posted on August 8, 2019 by Sitemaster
Posted on April 24, 2019 by Sitemaster
A media release issued yesterday by Progenics Pharmaceuticals states that the investigational imaging agent 18F-DCFPyL changed physician behavior in the management of biochemically recurrent prostate cancer in > 65 percent of patients. … READ MORE …
Filed under: Uncategorized | Tagged: 18F-DCFPyL, biochemical, change, CT, imaging, Management, PET, recurrence, scan | Leave a comment »
Posted on April 5, 2019 by Sitemaster
A new article in the most recent issue of the Journal of Urology provides recommendations for clinicians as to the appropriate, current use of “next-generation” imaging in the treatment of advanced prostate cancer. … READ MORE …
Filed under: Uncategorized | Tagged: imaging, next generation, PET scan, RADAR, recommedndation | 7 Comments »
Posted on October 5, 2018 by Sitemaster
In a media release issued earlier this morning, Progenics Pharmaceuticals has announced the outcome of a Phase II/III trial of their proprietary, PSMA-targeted imaging agent PyL (also known as 18F-DCFPyL) for identification of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: 18F-DCFPyL, imaging, PET, PSMA, PyL | 8 Comments »
Posted on June 26, 2018 by Sitemaster
Early this morning, Progenics Pharmaceuticals announced completion of enrollment of patients in the Phase II/III OSPREY trial of a new PSMA-targeted PET/CT imaging agent for detection of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: imaging, OSPREY, Progenics, PSMA, PyL | 1 Comment »
Posted on April 4, 2018 by Sitemaster
Nearly 30 years ago, when your sitemaster first attended a prostate cancer meeting (in 1989) related to the upcoming approval of a new drug called flutamide, he doesn’t remember there being a single clinician at the meeting who was female — out of the 150 or so urologists and medical oncologists who had been invited. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, Diagnosis, future, imaging, research, Treatment | 6 Comments »
Posted on March 6, 2018 by Sitemaster
A group of Italian researchers have apparently shown that a copper-64 dichloride-based radiotracing agent (64CuCl2) is better than currently-used 18FCl radiotracers in the detection of biochemically recurrent prostate cancer with PET/CT scans … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: copper-64, imaging, PET/CT, radiotracer, scan | 3 Comments »
Posted on October 13, 2017 by Sitemaster
So for those currently dissatisfied with the capabilities of 1.5 T and 3 T MRI imaging technology, the US Food and Drug Administration has just approved a 7 T MRI device called a “Siemens Magnetom Terra”. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: 7-T, imaging, MRI | Leave a comment »
Posted on September 19, 2017 by Sitemaster
Dr. Zachary Klaassen and UroToday have provided us with four more interesting summaries of presentations by faculty at the European Association for Urology (EAU)’s meeting in Vienna last weekend. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: biomarkers, care, focal, functional, genomics, imaging, molecular, patient-centered, therapy | 4 Comments »
Posted on August 25, 2017 by Sitemaster
Two recent papers by Sabouri et al. have suggested that a new MRI techique known as “luminal water imaging” may be able to improve the ability of MR scans to identify and grade prostate cancer prior to biopsy. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: Diagnosis, fraction, imaging, luminal, MRI, staging, water | 2 Comments »
Posted on August 8, 2017 by Sitemaster
A new paper in the Journal of Nuclear Medicine has reported the first use of [11C]sarcosine in combination with PET/CT scanning as a technique for imaging prostate cancer in man. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: carbon-11, imaging, PET/CT, sarcosine, scan | Leave a comment »
Posted on July 20, 2017 by Sitemaster
Our next CureTalks program will be on the evolving role of imaging in the diagnosis and management of prostate cancer on Thursday, July 27, at 5:00 p.m. Pacific / 8:00 p.m. Eastern time. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: CureTalk, imaging, Westphalen | Leave a comment »
Posted on April 20, 2017 by Sitemaster
As regular readers are well aware, there has for a while been an increase in the importance of new forms of high quality imaging studies in the diagnosis, work-up, and monitoring of men with prostate cancer (localized, locally advanced, and advanced). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: director, imaging, prostate | 1 Comment »
